4
Changes in Ownership
Axsome Therapeutics, Inc. Filed Acc 0001193125-26-021377
Chief Commercial Officer sold 7,500 shares at $184.44 ($1,383,300)
- Chief Commercial Officer acquired 7,500 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Maizel Ari · Chief Commercial Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-01-21 | Exercise or conversion : show line 1 in the form 10b5-1 | +7,500 | $70.73 | $530,475 | 7,500 | D |
| 2026-01-21 | Sale : show line 2 in the form 10b5-1 | −7,500 | $184.44 | $1,383,300 | 0 | D |
| Open-market sales · 7,500 sh · avg $184.44 · $1,383,300 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-01-21 | Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (Right to Buy) | −7,500 | 31,210 | D |
Loading xslF345X05/ownership.xml…